CD274 and neoplasm: In conclusion, although statistical comparisons were not conducted, this subpopulation analysis of data for patients enrolled in Asia in the KEYNOTE-062 study indicates that pembrolizumab monotherapy was associated with numerically improved OS outcomes compared with chemotherapy alone for patients with advanced GC/GEJC with PD-L1 CPS ≥1 and CPS ≥10 tumours.